En-tête de navigationNavigation principaleSuiviFiche


Unité de recherche
INNOSUISSE
Numéro de projet
25598.2 PFNM-NM
Titre du projet
Illuneo: a non-invasive, continuous blood glucose bedside measurement for preterm infants at the neonatal intensive care unit
Titre du projet anglais
Illuneo: a non-invasive, continuous blood glucose bedside measurement for preterm infants at the neonatal intensive care unit

Textes relatifs à ce projet

 AllemandFrançaisItalienAnglais
Description succincte
Anzeigen
-
-
Anzeigen
Résumé des résultats (Abstract)
Anzeigen
-
-
Anzeigen

Textes saisis


CatégorieTexte
Description succincte
(Allemand)
Illuneo: a non-invasive, continuous blood glucose bedside measurement for preterm infants at the neonatal intensive care unit
Description succincte
(Anglais)
Illuneo: a non-invasive, continuous blood glucose bedside measurement for preterm infants at the neonatal intensive care unit
Résumé des résultats (Abstract)
(Allemand)
The aim is to prevent impaired brain development in extreme and very preterm neonates in addition to reducing pain, infection risks, and to lowering costs for hospitals via continuous, non-invasive, transdermal, auto-calibrating glucose monitoring with passive diffusion. We developed, patented and tested in vitro a novel measurement principle with two parallel measurements for calibrating skin resistance. We now need to prove our new principle in a clinical pilot trial.
Résumé des résultats (Abstract)
(Anglais)
The aim is to prevent impaired brain development in extreme and very preterm neonates in addition to reducing pain, infection risks, and to lowering costs for hospitals via continuous, non-invasive, transdermal, auto-calibrating glucose monitoring with passive diffusion. We developed, patented and tested in vitro a novel measurement principle with two parallel measurements for calibrating skin resistance. We now need to prove our new principle in a clinical pilot trial.